SpaceX Lockup Test Passed, But the Equity Supply Flood Is Just Beginning

The Lockup That Didn’t Break

Wall Street spent weeks bracing for August 6. When SpaceX (SPCX) went public in June at $135 a share, the first post-IPO lockup was always going to be the moment of truth: 911.5 million insider shares — more than were sold in the IPO itself — would become free-trading, roughly tripling the public float and testing whether the market could absorb roughly $100 billion in newly liquid stock.^[1]

The consensus expectation was downward pressure, possibly severe. Reuters reported that the staggered lockup schedule will eventually free 12.9 billion additional shares by mid-2027, making the August 6 expiry merely the first — and by some measures the gentlest — of a long series of supply events.^[1] Business Insider framed the stock as already trading below its IPO price heading into the unlock, a setup that historically compounds lockup selling pressure.

The outcome confounded the consensus. SpaceX shares rose on the day of the expiry and then surged 35% over the next five trading sessions, adding roughly $500 billion in market capitalization and vaulting back above the $135 IPO price.^[2] Bloomberg noted the shares climbed even as investors digested the release of the full 911.5 million-share tranche.^[3]

What would have to be true for the optimistic read to hold? The simplest explanation is that the buyer base was larger and more patient than sellers assumed. Retail enthusiasm, index-mechanic flows, and the scarcity premium of a Musk-affiliated public asset combined to absorb supply that looked terrifying on paper. A less comforting read is that the selling simply hasn’t arrived yet — that insiders are waiting for higher prices before trimming, and the real test comes when subsequent, larger tranches unlock. The data can support both interpretations, and the distinction matters enormously for the months ahead.

Biotech IPOs Lead a Broader Issuance Revival

While SpaceX dominated headlines, the US IPO calendar quietly had its busiest week in months. Renaissance Capital counted six IPOs and five SPACs pricing during the week of August 3, with four clinical-stage biotechs collectively raising $1.17 billion — every one of them upsized at pricing.^[4]

The deals were not marginal. Braveheart Bio (BRVE) priced above range at $18, raising $383 million at a $1.6 billion market cap and finishing its first week up 67%.^[4] Latigo Biotherapeutics (LTGO) raised $346 million at the top of its range for a $1.3 billion valuation. Attovia Therapeutics (ATTO) priced at the high end for $289 million. BlossomHill Therapeutics (BLSM) raised $150 million at midpoint. All four upsized — the deal structure itself signaling that underwriters saw more demand than the original filing anticipated.^[5]

The Renaissance IPO Index rebounded 8.6% for the week, outpacing the S&P 500’s 3.6% gain, and returned to above +20% year-to-date after July’s AI-driven sell-off.^[5] The index’s year-to-date gain of 18.8% through August 6 compares favorably to the S&P 500’s 13.4%.^[4]

The pattern here is consistent with a market that has regained its appetite for risk-priced equity, at least in sectors where clinical data provides a fundamental anchor. MedCity News noted that investors are demanding at least some clinical evidence before funding a debut — a higher bar than the pre-revenue IPOs that characterized the 2021 peak, and one that may be filtering for higher-quality supply.^[5]

Secondaries and Exits: The Quiet Supply

New listings are only one channel. Secondary offerings — existing shareholders selling into the public market — are often the larger and less heralded source of equity supply.

On August 11, OPENLANE (OPLN) announced a secondary offering of 8 million shares by Ignition Acquisition Holdings LP, a fund advised by Apax Partners.^[6] The shares priced at $34.36, generating approximately $274.9 million in gross proceeds to the selling stockholder.^[6] OPENLANE concurrently authorized a share repurchase to absorb a portion of the supply, but the buyback covers only a fraction of the 8 million shares — a structure that replicates, in miniature, the broader market dynamic of corporate demand partially offsetting investor supply.^[7] OPENLANE shares dropped 5.3% in pre-market trading following the announcement.^[7]

The private-equity secondaries market tells a parallel story. Evercore’s H1 2026 review recorded $121 billion in secondary-market volume, up 19% year-over-year, with GP-led deals reaching $65 billion (up 35%) and surpassing LP-led volume for the first time.^[7] The full-year projection sits in the $250–260 billion range.^[7] This is the plumbing layer: limited partners needing liquidity, GPs engineering continuation funds, and the overall pressure to return capital to investors pushing distribution pipelines wider. It does not show up directly in public-market supply-demand tables, but it shapes the risk appetite and balance-sheet capacity of the institutions that also price IPOs and secondaries.

Goldman’s Framework: $1.3 Trillion In, $1.1 Trillion Out

Goldman Sachs strategist Ben Snider has put numbers on the supply-demand question that the SpaceX lockup and the biotech IPO wave both raise. The framework, summarized in a June strategy note and elaborated in August coverage, projects US corporate buybacks reaching $1.3 trillion in 2026, against equity issuance of $1.1 trillion — a net corporate demand figure of roughly $200 billion.^[8]

The key qualitative finding is that follow-on equity issuance has risen to levels not seen since 2021, driven substantially by AI-related capital spending needs.^[9] US corporations raised $252 billion in the equity markets through the first half of 2026.^[9] Goldman’s view is that this is more a normalization than a market-threatening boom — buybacks plus debt financing are expected to absorb much of the incremental supply.^[7]

The Axios framing from SpaceX’s June IPO is apt: SpaceX’s arrival heralded “a wave of new stock” hitting the market, with the potential to tilt supply-demand dynamics that have quietly supported valuations.^[8] The question is whether net corporate demand stays positive as that wave crests — and whether the SpaceX lockup outcome is a leading indicator of market resilience or a one-off driven by a unique asset’s scarcity premium.

The Staggered Lockup Calendar: What’s Ahead

The SpaceX lockup schedule is not a single event but a series, and the August 6 expiry was the first — and the smallest proportional tranche relative to what remains. Reuters reported a staggered schedule that will free an additional 12.9 billion shares by mid-2027.^[1] The next expiration falls on August 20.^[2]

Here is what to track:

What to Watch Next

1. SpaceX August 20 lockup. The first expiry was absorbed with ease. The second tranche will reveal whether that was genuine demand or insiders simply waiting for a better exit price. If the stock holds, the “lockup cliff” narrative weakens considerably. If it falters, the August 6 surge looks more like a short squeeze than durable bid.

2. Biotech IPO pricing sustainability. Four upsized biotech deals in one week is a signal, not a trend. Watch whether the September calendar maintains the pace — and whether post-Performance returns hold. First-day pops of 67% (BRVE) are exciting; what matters for supply-demand is whether the stock retains that level after the initial excitement fades.

3. The buyback-issuance spread. Goldman’s $1.3T vs. $1.1T framework is a full-year projection. Q3 and Q4 buyback execution rates — typically strongest in August and September — will determine whether net corporate demand stays positive. If AI-capex-driven issuance accelerates faster than buyback announcements, the cushion thins.

4. Private-equity secondaries velocity. Evercore’s $121B H1 figure and the shift to GP-led deals signal that PE liquidity pressure is building. If LPs accelerate distributions via secondary sales, the capital recycled into public equities could support demand — or, if redeployed into new fund commitments, could compete with it.

The base case, extrapolating from current trajectory: equity supply is normalizing toward 2021 levels, but corporate demand is keeping pace. The 40 scenario — the one that would matter — is a simultaneous acceleration of AI-capex issuance, a SpaceX lockup tranche that finally overwhelms the bid, and a buyback slowdown if earnings decelerate. None of those is visible in the current data. But the SpaceX schedule alone guarantees that the supply question will be retested at least monthly through mid-2027. Each expiry is a data point. The first one said the market can absorb. The next ones will say whether that was luck or structure.